Supernus Pharma Stock Analysis, Valuation (NASDAQ:SUPN)
Take a look at Amigobulls Supernus Pharma stock analysis video. Our SUPN analysis video highlights revenue and profit trends along with other important metrics such as valuation to find what makes the stock attractive.
Note: Amigobulls stock rating is our opinion based on the historical performance of the company's fundamentals. It is not indicative of the future performance of the stock.
Supernus Pharmaceuticals Inc Stock Rating 4.3/5
We at Amigobulls use various financial measures including profit margins, revenue growth and dividends for SUPN stock analysis. Supernus Pharma valuation forms a crucial part of our stock analysis. Our Supernus Pharma stock rating is based on company's fundamentals like balance sheet risk and cash flow position.
Should you buy SUPN stock?
- Supernus Pharma sales grew by 57.1% year on year in 2018-03.
- Revenue growth has been tremendous with a compounded annual growth of 198.2 over the last 5 years.
- Supernus Pharma had a healthy average operating margin of 34.06 over the last 4 quarters.
- Net margins came in at average 21.9% for Supernus Pharma over the last twelve months.
- Supernus Pharma has an attractive ROIC (Return on Invested Capital) of 42.2
- Supernus Pharma has a good Return On Equity (ROE) of 28.1.
- Supernus Pharma has a healthy FCF (Free Cash Flow) margin of 29.7.
Supernus Pharma Related Company Stock Videos
Amigobulls Supernus Pharma stock analysis helps in evaluating the financial statements of a company to arrive at a conclusion about the fair value of SUPN stock. The fundamentals of a company are vital to identify long-term investment opportunities.
Among the financials of the company, Supernus Pharma revenue growth along with the profit or net income give a clear picture of the financial health. One can also combine technical analysis and fundamental analysis to get a holistic picture about SUPN stock.